 Experience digoxin immune Fab ovine patients renal impairment Digibind purified antigen fragment Fab immunoglobulin antibodies digoxin Studies animals renal excretion accounts substantial portion Fab elimination elimination antidigoxin Fab fragments patients renal impairment unclear digoxin possible recurrence toxicity light potential recrudescent digitalis toxicity release bound digoxin author records patients impaired renal function Digibind Data available sources original multicenter investigation Digibind patients life-threatening digoxin digitoxin toxicity postmarketing surveillance study patients Digibind reports literature Burroughs Wellcome Co physician experience antidigoxin Fab Sixty percent patients multicenter trial patients postmarketing surveillance trial degree renal impairment Patients poor renal function evidence decreased effectiveness safety terms percent patients onset effect evidence recrudescence sources authors patients Fab anephric patients evidence recrudescent toxicity patient complete resolution digoxin-induced third-degree atrioventricular AV block AV block days Fab treatment days case clinical evidence recrudescence likely alternative explanations clinical findings